The Food and Drug Administration on Wednesday approved a groundbreaking new drug for advanced pancreatic cancer, offering U.S. patients a more effective treatment against one of the deadliest types of cancer. FDA officials gave expedited approval to the first-of-a-kind pill, called daraxonrasib, which blocks a mutated protein that fuels tumor growth in more than 90%…
Drugmaker Moderna’s stock more than doubled on Wednesday morning after the company announced a successful experimental mRNA vaccine to treat melanoma, the deadly skin cancer from which more than 8,500 people are expected to die this year. Moderna and Merck, its drug development partner, said the novel treatment prevented melanoma from returning or spreading in a…
Eli Lilly said Wednesday it is suing six companies selling versions of its experimental weight-loss drug retatrutide, calling it the beginning of a concerted effort to crack down on a vast illicit market. That market has boomed even though retatrutide is still being studied in clinical trials and hasn’t been approved by the Food and…
The U.S. Food and Drug Administration has approved a new seasonal flu vaccine from Moderna that uses mRNA technology, the drugmaker announced Wednesday. mFLUSIVA, approved for adults ages 50 and older, is the first influenza vaccine using mRNA technology to receive FDA approval. “This approval also reflects the ongoing potential of our mRNA platform to…
A generic version of the brand-name allergy medication Zyrtec is under recall across the U.S. due to potential cross-contamination with a heartburn drug, according to the Food and Drug Administration. Drugmaker Unique Pharmaceutical Laboratories is voluntarily recalling antihistamine drugs, commonly used to treat seasonal allergies, over potential cross-contamination with ranitidine, a heartburn drug. Unique Pharmaceutical…
Novo Nordisk sued competitor Eli Lilly on Tuesday, alleging the drugmaker engaged in false advertising by claiming its GLP-1 drugs are superior to Novo’s. The lawsuit accuses Eli Lilly of misleading consumers by using outdated clinical trial data to make Zepbound and Mounjaro appear more effective than Novo’s drugs, Wegovy and Ozempic, for weight loss…
